CHCWM – Cancer & Hematology Centers of West Michigan

MERCK MK7864A-007

 

    • A Randomized, Double-Blind, Phase 3 Study of MK-7684A Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy as First Line Treatment for Participants With Metastatic Non-Small Cell Lung Cancer
    • PI: Dr Chen
    • Available at: CHCWM – Muskegon, Holland Cancer Center, Lacks Cancer Center at Saint Mary’s, Lemmen-Holton Cancer Pavilion